Skip to content
value.today

Lensar, Inc.

LNSR
$79 Mmarket cap on Oct 9, 2026+65.2% since Jan 2024
Compare
World rank
#19,610
Revenue
$58 M
For year ending December-2025
Net income
$-34 M
-58.7% margin
SEC filing
Employees
150
As of December 31, 2025
SEC filing

Lensar, Inc. in brief

Lensar, Inc. is a listed company in the Healthcare sector, based in Orlando, Florida, USA. Its market value was $79 M on 9 October 2026, which makes it the 19,610th largest listed company in the world and the 3,640th largest in the USA on this site. In the year to December 2025 it had sales of $58 M and a net loss of $34 M. It employs about 150 people and Nicholas T. Curtis is its chief executive. By market, the largest shares of its 2025 sales came from USA (59%), Europe (14%) and Asia (Excluding South Korea) (14%). Its shares trade under the symbol LNSR (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Lensar, Inc.

We are a commercial-stage medical device company focused on designing, developing and marketing advanced laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Our current systems, the LENSAR Laser System, or LLS, and ALLY Robotic Cataract Laser System®, or ALLY System, or collectively, the Systems, incorporate a range of proprietary technologies designed to assist the surgeon in obtaining better visual outcomes, efficiency and reproducibility by providing advanced imaging, simplified procedure planning, efficient design and precision. We believe the cumulative effect of these technologies results in laser systems that can be quickly and efficiently integrated into a surgeon’s existing practice, is easy to use and provides surgeons the ability to deliver improved visual outcomes with enhanced precision and the ability to do so consistently. The ALLY System combines all of the features from our LLS with a dual-modality laser, integrated in a small, compact cataract treatment system that is designed to allow surgeons to perform sterile cataract surgery in a single operating room. This system is designed to be a significant medical advancement and provide improved efficiency and financial benefit to a surgeon’s practice and to ambulatory surgery centers, or ASCs. The ALLY System received clearance from the U.S. Food and Drug Administration, or FDA, in June 2022, and we executed a controlled and targeted initial launch of the ALLY System in August 2022. The ALLY System is available to all U.S. and EU cataract surgeons and has also received regulatory clearance in India, Taiwan, as well as certain other countries.

From the company's annual report filed with the US SEC: read the report

Lensar, Inc. timeline

3 events, 2005–2025
  1. 2005
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2006
  4. ✎
    Renamed LensAR Inc
    Formerly LaserSoft Vision Inc.
  5. 2025
  6. 💰
    Record revenue of $58 million
    FY2025, the highest of the 7 years on record.

Events of Lensar, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$38 M$76 M$114 M$152 M2023202420252026

World rank over time

▲ up 5,059 places since 2022
2022-01-07: #24741#24,74120222022-12-25: #27440#27,44020222023-07-30: #26620#26,62020232024-01-05: #25049#25,04920242026-03-08: #9495#9,49520262026-08-01: #17347#17,34720262026-10-09: #19682#19,6822026

Rank in USA: #4,730 (Jan 2022) · #5,066 (Dec 2022) · #4,895 (Jul 2023) · #4,077 (Jan 2024) · #1,832 (Mar 2026) · #3,418 (Aug 2026) · #3,619 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
2.4×
Price / sales (TTM)
1.3×
Price / book
—
Free cash flow yield
-18.8%
Net margin (TTM)
56.1%
Operating margin
-42.1%
Return on equity
—
Liabilities / assets
117.1%
Revenue growth
+9.3%
R&D / revenue
9.6%
Revenue per employee
$390 K
Profit per employee
$-229 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2019: revenue $31M, net income $-15M$31MFY19Fiscal year ending Dec 2020: revenue $26M, net income $-20M$26MFY20Fiscal year ending Dec 2021: revenue $34M, net income $-20M$34MFY21Fiscal year ending Dec 2022: revenue $35M, net income $-20M$35MFY22Fiscal year ending Dec 2023: revenue $42M, net income $-14M$42MFY23Fiscal year ending Dec 2024: revenue $53M, net income $-31M$53MFY24Fiscal year ending Dec 2025: revenue $58M, net income $-34M$58MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$58M+9.3%$-25M$-34M-58.7%
Dec 2024$53M+26.9%$-11M$-31M-58.7%
Dec 2023$42M+19.2%$-12M$-14M-34.1%
Dec 2022$35M+2.6%$-20M$-20M-56.3%
Dec 2021$34M+30.6%$-20M$-20M-56.9%
Dec 2020$26M-13.6%$-19M$-20M-74.9%
Dec 2019$31M—$-13M$-15M-48.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-15M$0M$-15M$-2.87—
Dec 2024$-2M$0M$-2M$-2.73—
Dec 2023$-10M$0M$-10M$-1.31—
Dec 2022$-15M$0M$-15M$-1.96—
Dec 2021$-9M$0M$-9M$-2.09—
Dec 2020$-14M$0M$-14M$-4.28—
Dec 2019$-13M$0M$-13M$-13.70—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$60M
Net income, trailing 12 months
$34M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $17M, net income $-19M$17MDec ’24Three months to Mar 2025: revenue $14M, net income $-27M$14MMar ’25Three months to Jun 2025: revenue $14M, net income $-2M$14MJun ’25Three months to Sep 2025: revenue $14M, net income $-4M$14MSep ’25Three months to Dec 2025 (from the annual report): revenue $16M, net income $-1M$16MDec ’25Three months to Mar 2026: revenue $13M, net income $36M$13MMar ’26Three months to Jun 2026: revenue $17M, net income $4M$17MJun ’26Three months to Sep 2026: revenue $14M, net income $-5M$14MSep ’26

Latest quarter to Sep 2026: revenue $14M (-1.3% on a year earlier), net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Lensar, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$58 M
Operating income
$-25 M
Net income
$-34 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$71 M
Total liabilities
$84 M
Total equity
$-26 M

As of December-2025

Top 67 institutional investors in Lensar, Inc.#

As of Sep 30, 2026
67 institutions held 4.1 M shares (about 32.9% of the shares outstanding) on Sep 30, 2026. The ten largest hold 22.4%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Lensar, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Brandes Investment Partners, LP1,254,384+178,984 (+16.64%)10.20%$8 MNov 16, 2026
2Vanguard Capital Management LLC402,8060 (0.00%)3.28%$3 MNov 13, 2026
3RBF Capital, LLC227,915+39,254 (+20.81%)1.85%$2 MNov 13, 2026
4Marshall Wace, LLP184,000New1.50%$1 MNov 13, 2026
5BlackRock, Inc.166,384-18,649 (-10.08%)1.35%$1 MNov 13, 2026
6CSS Llc/il120,450-43,000 (-26.31%)0.98%$1 MNov 16, 2026
7Geode Capital Management, LLC111,703-2,628 (-2.30%)0.91%$1 MNov 6, 2026
8Mink Brook Asset Management LLC100,000New0.81%$1 MNov 13, 2026
9DCF Advisers, LLC94,000-24,217 (-20.49%)0.76%$1 MNov 4, 2026
10Millennium Management LLC88,229-32,451 (-26.89%)0.72%$1 MNov 16, 2026
11Dimensional Fund Advisors LP72,891-78,718 (-51.92%)0.59%$0 MNov 4, 2026
12State Street Corp71,983-9,000 (-11.11%)0.59%$0 MNov 12, 2026
13Citadel Advisors LLC71,278+35,531 (+99.40%)0.58%$0 MNov 16, 2026
14Yakira Capital Management, Inc.64,918-18,370 (-22.06%)0.53%$0 MNov 13, 2026
15Vanguard Fiduciary Trust Co64,233+6,402 (+11.07%)0.52%$0 MNov 13, 2026
16Gabelli Funds LLC59,0000 (0.00%)0.48%$0 MNov 12, 2026
17Jane Street Group, LLC55,991+35,628 (+174.96%)0.46%$0 MNov 12, 2026
18Susquehanna International Group, LLP54,496+10,241 (+23.14%)0.44%$0 MNov 16, 2026
19Dynamic Technology Lab Private Ltd54,1660 (0.00%)0.44%$0 MNov 13, 2026
20Essex Investment Management Co LLC53,2580 (0.00%)0.43%$0 MOct 19, 2026
21Centiva Capital, LP50,602+1,350 (+2.74%)0.41%$0 MNov 13, 2026
22Goldman Sachs Group Inc49,171-10,358 (-17.40%)0.40%$0 MNov 16, 2026
23Hillsdale Investment Management Inc.46,000New0.37%$0 MNov 12, 2026
24Quinn Opportunity Partners LLC39,349+10,000 (+34.07%)0.32%$0 MNov 10, 2026
25LPL Financial LLC35,696+4,028 (+12.72%)0.29%$0 MNov 6, 2026
Show all 67: investors 26 to 67
Institutional investors 26 to 67 in Lensar, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26GTS Securities LLC33,974+8,970 (+35.87%)0.28%$0 MNov 16, 2026
27GAMCO Investors, Inc. Et Al33,0000 (0.00%)0.27%$0 MNov 12, 2026
28Deltec Asset Management LLC32,500-32,500 (-50.00%)0.26%$0 MOct 26, 2026
29Squarepoint Ops LLC30,484New0.25%$0 MNov 9, 2026
30Royal Bank Of Canada28,452+4,988 (+21.26%)0.23%$0 MNov 16, 2026
31Morgan Stanley28,119+19,627 (+231.12%)0.23%$0 MNov 13, 2026
32Envestnet Asset Management Inc26,825+3,503 (+15.02%)0.22%$0 MNov 16, 2026
33XTX Topco Ltd26,267New0.21%$0 MNov 16, 2026
34Renaissance Technologies LLC25,000New0.20%$0 MNov 12, 2026
35Northern Trust Corp21,992-25 (-0.11%)0.18%$0 MNov 16, 2026
36HRT Financial LP20,427+9,486 (+86.70%)0.17%$0 MNov 13, 2026
37Occudo Quantitative Strategies LP19,989New0.16%$0 MNov 16, 2026
38Sanctuary Advisors, LLC17,295+498 (+2.96%)0.14%$0 MNov 13, 2026
39Atria Investments, Inc16,849+1,666 (+10.97%)0.14%$0 MOct 15, 2026
40State of Wyoming16,718New0.14%$0 MOct 28, 2026
41Murchinson Ltd.13,2230 (0.00%)0.11%$0 MNov 13, 2026
42Legato Capital Management LLC12,5690 (0.00%)0.10%$0 MNov 10, 2026
43&partners11,403+849 (+8.04%)0.09%$0 MNov 16, 2026
44UBS Group AG10,936-74,698 (-87.23%)0.09%$0 MNov 10, 2026
45Nuveen, LLC8,078New0.07%$0 MNov 10, 2026
46Russell Investments Group, Ltd.5,007-4,836 (-49.13%)0.04%$0 MNov 6, 2026
47UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC3,509+2,007 (+133.62%)0.03%$0 MNov 16, 2026
48Vanguard Global Advisers, LLC3,1780 (0.00%)0.03%$0 MNov 13, 2026
49National Bank Of Canada /fi/2,0500 (0.00%)0.02%$0 MNov 16, 2026
50FMR LLC2,019-1,170 (-36.69%)0.02%$0 MNov 10, 2026
51Tower Research Capital LLC (TRC)1,965+1,701 (+644.32%)0.02%$0 MNov 16, 2026
52Jpmorgan Chase & Co1,508+1,083 (+254.82%)0.01%$0 MNov 12, 2026
53Fifth Third Bancorp1,4980 (0.00%)0.01%$0 MNov 5, 2026
54GAMMA Investing LLC893-370 (-29.30%)0.01%$0 MOct 8, 2026
55Wells Fargo & Company/mn318-50 (-13.59%)0.00%$0 MNov 16, 2026
56Osaic Holdings, Inc.2730 (0.00%)0.00%$0 MNov 12, 2026
57BNP Paribas Financial Markets233-146 (-38.52%)0.00%$0 MNov 12, 2026
58Caitong International Asset Management Co., Ltd191+184 (+2628.57%)0.00%$0 MOct 29, 2026
59Steward Partners Investment Advisory, LLC1690 (0.00%)0.00%$0 MNov 13, 2026
60Farther Finance Advisors, LLC1490 (0.00%)0.00%$0 MOct 8, 2026
61PNC Financial Services Group, Inc.135-216 (-61.54%)0.00%$0 MNov 6, 2026
62Harbour Investments, Inc.750 (0.00%)0.00%$0 MNov 9, 2026
63SBI Securities Co., Ltd.57-1 (-1.72%)0.00%$0 MOct 22, 2026
64Lanark Financial, Inc.410 (0.00%)0.00%$0 MOct 26, 2026
65Blume Capital Management, Inc.70 (0.00%)0.00%$0 MOct 26, 2026
66Barclays PLC1-456 (-99.78%)0.00%$0 MNov 6, 2026
67Buck Wealth Strategies, LLC10 (0.00%)0.00%$0 MOct 28, 2026

Mutual funds holding Lensar, Inc.#

50 funds hold shares worth $8 M (about 6.7% of the company). Since their previous reports 11 added shares and 48 sold, selling $3 M net.
Mutual funds holding Lensar, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Brandes Small Cap Value FundBrandes Investment Partners LP532,616$3 M2.6%0.48%+9.9%Jun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.275,971$2 M1.4%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.101,379$1 M0.50%<0.01%−0.4%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC52,439$0 M0.26%<0.01%+3.2%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.48,568$0 M0.24%<0.01%+2.0%May 31, 2026
🇺🇸 U.S. Targeted Value PortfolioDimensional Fund Advisors LP53,149$0 M0.26%<0.01%−8.1%Jul 31, 2026
🇺🇸 1290 VT GAMCO Mergers & Acquisitions PortfolioEquitable Investment Management Group, LLC33,000$0 M0.16%0.11%no changeJun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors32,515$0 M0.16%0.01%+40%Jun 30, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP35,350$0 M0.18%<0.01%−12%Jul 31, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP22,817$0 M0.11%<0.01%no changeJul 31, 2026
🇺🇸 The Gabelli ABC FundGabelli Funds, LLC20,000$0 M0.10%0.03%no changeJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC17,123$0 M0.08%<0.01%no changeMay 31, 2026
🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P.14,533$0 M0.07%<0.01%+1.4%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC14,419$0 M0.07%<0.01%+9.0%May 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP16,558$0 M0.08%<0.01%−21%Jul 31, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors11,740$0 M0.06%<0.01%−95%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.9,127$0 M0.05%<0.01%+3.0%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC8,155$0 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 Nuveen Nasdaq 100 Dynamic Overwrite FundNuveen Fund Advisors, LLC7,859$0 M0.04%<0.01%−56%Jun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.7,146$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Invesco Russell 2000 Dynamic Multifactor ETFInvesco Capital Management LLC5,544$0 M0.03%0.01%newMay 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.5,198$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors4,257$0 M0.02%<0.01%−95%Jun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.4,846$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company3,936$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC2,176$0 M0.01%<0.01%+21%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC1,996$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 U.S. Small Cap Value PortfolioDimensional Fund Advisors LP1,627$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 SA U.S. Small Company FundFocus Advisor Solutions, LLC1,385$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION1,200$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust1,009$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC866$0 M<0.01%<0.01%−95%Jun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.802$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 LVIP Dimensional U.S. Core Equity 1 FundLincoln Financial Investments Corporation606$0 M<0.01%<0.01%−63%Jun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC588$0 M<0.01%<0.01%−95%Jun 30, 2026
🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP682$0 M<0.01%<0.01%−97%Jul 31, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC449$0 M<0.01%<0.01%+8.5%May 31, 2026
🇺🇸 JNL/DFA U.S. Core Equity FundJackson National Asset Management, LLC440$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC350$0 M<0.01%<0.01%−41%May 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC353$0 M<0.01%<0.01%−40%May 31, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC329$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC137$0 M<0.01%<0.01%−95%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC118$0 M<0.01%<0.01%−95%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS98$0 M<0.01%<0.01%−95%Jun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC84$0 M<0.01%<0.01%−94%Jun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC66$0 M<0.01%<0.01%−94%Jun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.54$0 M<0.01%<0.01%+17%Jun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC32$0 M<0.01%<0.01%−94%Jun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC22$0 M<0.01%<0.01%−94%Jun 30, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP4$0 M<0.01%<0.01%no changeJul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 50 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Lensar, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
13
since
$21 K$0Nov 2023: bought $6 K (4 trades), sold $0 (0 trades)Nov 23Aug 2024: bought $21 K (9 trades), sold $0 (0 trades)AugSep 2024: bought $3 K (1 trades), sold $0 (0 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
Lensar, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Gary M. WinerDirectorGrant or award+4,169$4.530$19 K109,804Form 4
filed Nicholas T. CurtisChief Executive Officer, DirectorGrant or award+130,662——1.12 MForm 4
filed Gary M. WinerDirectorGrant or award+17,421——105,635Form 4
filed Aimee S. WeisnerDirectorGrant or award+17,421——110,368Form 4
filed Alan B. ConnaughtonChief Operating OfficerGrant or award+34,843——389,173Form 4
filed Richard L. LindstromDirectorGrant or award+17,421——263,831Form 4
filed Kendra WongPrincipal Accounting OfficerGrant or award+13,066——56,481Form 4
filed William J. LinkDirectorGrant or award+17,421——568,062Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Lensar, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
306,208
2.6% of shares · 6.77 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-9 reverse split

Trading halts

  • 2026-03-16 20:25 UTC, code T3, resumed 21:00 UTC
  • 2025-03-24 11:55 UTC, code T3, resumed 12:30 UTC

Fails to deliver

  • : 3 shares at $6.45
  • : 50 shares at $8.44
  • : 1,191 shares at $8.72
  • : 12 shares at $8.09
  • : 848 shares at $8.27

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Lensar, Inc. scorecard#

Passes 9 of the 19 checks that could be worked out: strongest in growth (4 of 6), weakest in profitability (1 of 4). Fiscal year 2025; market cap of Oct 9, 2026.

  • Valuation3 of 5
    • ✓P/E below its peers' median2.4×P/E 2.4× against Healthcare's median of 30.0×.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • ✓Price to sales below its peers' median1.3×Price to sales 1.3× against Healthcare's median of 3.8×.
    • ✗Free cash flow yield above 5%-18.8%Free cash flow is -18.8% of the market value.
    • ✓Earnings yield above the 10-year Treasury yield42.6%Earnings yield 42.6% against the 10-year Treasury's 5.15% on 2026-11-13.
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth4 of 6
    • ✓Revenue grew in the newest year9.2%Revenue up 9.2% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years18.2%18.2% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median18.2%18.2% a year against Healthcare's median of 8.5% (549 companies).
    • ✗Earnings per share grew in the newest year-2.87 vs -2.73Diluted EPS -2.87 in fiscal 2025 against -2.73 the year before (report's currency).
    • ✗Net income higher than five years earlier-$34 M-$34 M in fiscal 2025 against -$20 M in 2020.
    • ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
  • Profitability1 of 4
    • ✗Profitable in the newest year-$34 MNet income -$34 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-42.1%-42.1% against Healthcare's median of -7.7% (674 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-42.1%-42.1% in fiscal 2025 against -57.1% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities1.1×Current ratio 1.15 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-3.13Z-score -3.13 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year3.8%Diluted shares up 3.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Lensar, Inc.'s statements, beside the median of Healthcare.

Lensar, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-42.1%-7.7%
Net margin-58.7%-8.1%
Revenue growth, 3 years a year18.2%8.5%
Revenue growth9.3%10.2%
Free cash flow margin-25.5%-1.3%

2of 8on the Piotroski tests of financial strength

  • Net loss of $34 million, the 7th loss-making year in a row.
  • Free cash flow was negative: -$15 million.
  • Shareholders' equity is negative: -$26 million.
  • Revenue has grown 5 years in a row.

Lensar, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Lensar, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019
Income statement
Revenue58534235342631
Cost of revenue31282115171217
Research and development5.65.36.112127.67.6
Selling, general and administrative45262627242417
Operating income−25−11−12−20−20−19−13
Interest expense and finance costs—————1.32.0
Provision for credit losses−0.0−0.00.00.00.0−0.0—
Other non-operating income (expense)0.60.70.70.30.10.10.1
Income before tax−34−31−14−20−20−20−15
Net income including minority interests−34−31−14−20−20−20−15
Net income attributable to shareholders−34−31−14−20−20−20−15
Earnings per share, basic-2.87-2.73-1.31-1.96-2.09-4.28-13.70
Earnings per share, diluted-2.87-2.73-1.31-1.96-2.09-4.28-13.70
Shares, weighted average (basic)121211109.4——
Shares, weighted average (diluted)121211109.44.61.1
Balance sheet
Cash and cash equivalents1316211532414.6
Short-term investments5.06.23.4————
Receivables6.46.14.06.04.62.03.4
Inventory221116126.5138.1
Other current assets0.61.62.41.11.71.90.6
Current assets47424634455817
Property, plant and equipment0.50.70.70.60.80.80.7
Right-of-use (leased) assets2.62.52.12.63.23.70.9
Other intangible assets5.26.11112111213
Long-term investments——0.5————
Total assets71667056667935
Accounts payable196.04.05.42.72.51.6
Current liabilities411512118.78.57.8
Lease liabilities (non-current)2.02.11.82.32.83.30.3
Total liabilities84482214121265
Retained earnings−178−143−112−98−78−58−38
Shareholders' equity−264.933425567−31
Total liabilities and equity71667056667935
Shares outstanding1212111111111.1
Cash-flow statement
Share-based compensation3.12.75.56.66.99.00.1
Cash from operating activities−15−2.3−9.7−15−9.0−14−13
Capital expenditure−0.1−0.2−0.2−0.1−0.4−0.4−0.4
Intangible assets bought——————−1.7
Cash from investing activities1.3−2.2−4.2−0.1−0.4−0.3−2.1
Shares issued—————16—
Cash from financing activities100.120−2.00.45016
Change in cash−3.3−4.45.9−17−9.0361.3
Report10-K10-K10-K10-K10-K10-K10-K

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Lensar, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product(total)$46 M79%
  • Service(total)$6 M9.8%

Countries and regions

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where Lensar, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.

Lensar, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office$34 M59%
🇰🇷 South Korea$1 M1.1%

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Lensar, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.3 M
Mr. Curtis
Other top executives, average
$929 K
the CEO earned 2.5× this
$100 invested is now
$331
Lensar, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Mr. Curtis$2.3 M$3.2 M$929 K$331
2024Mr. Curtis$1.6 M$3.0 M$916 K$255

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Lensar, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 2 · Material agreement 2 · Agreement ended 2 · Shareholder vote 4 · Results announced 11

Lensar, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Shareholder vote8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Material agreementAgreement ended8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Agreement endedResults announced8-K
Shareholder vote8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

10 private funding rounds before listing

Private share sales · funding history

Private share sales of Lensar, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2023$20 MPrivate placement after listing$10 to $50 million1equity, optionsSEC
Jul 2014$16 MNo. 10$10 to $50 million2equitySEC
Dec 2013$10 MNo. 9$10 to $50 million14equitySEC
Aug 2013$17 MNo. 8$10 to $50 million3equitySEC
Nov 2012$5 MNo. 7$2 to $10 million3equitySEC
Mar 2012$24 MNo. 6$10 to $50 million2equitySEC
Dec 2011$1 MNo. 5Under $2 million1debt, optionsSEC
Oct 2011$4 MNo. 4$2 to $10 million1equitySEC
Aug 2011$5 MNo. 3$2 to $10 million2debt, optionsSEC
Jul 2010$7 MNo. 2$2 to $10 million2equitySEC
Jul 2009$7 MNo. 1$2 to $10 million3equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Lensar, Inc. compares in Healthcare

  • Market cap$79 M · higher than 24% of 2,013
  • Revenue$58 M · higher than 35% of 1,795
  • Net margin56.1% · higher than 99% of 1,485
  • Revenue growth9.3% · higher than 53% of 1,003
  • P/E ratio2.4× · lower than 99% of 605
  • Price / sales1.3× · lower than 77% of 1,071
  • FCF yield-18.8% · higher than 32% of 835
CompanyMarket capP/ENet marginRev. growth
Lensar, Inc.🇺🇸$79 M2.4×56.1%+9.3%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
UnitedHealth Group Incorporated🇺🇸$367.7 B23.1×3.5%+11.8%
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 9, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Lensar, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Lensar, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Lensar, Inc.? Suggest a correction